PL1660115T3 - Farmaceutyczna kombinacja G-CSF i PLGF użyteczna wobec komórek macierzystych krwi - Google Patents

Farmaceutyczna kombinacja G-CSF i PLGF użyteczna wobec komórek macierzystych krwi

Info

Publication number
PL1660115T3
PL1660115T3 PL04763431T PL04763431T PL1660115T3 PL 1660115 T3 PL1660115 T3 PL 1660115T3 PL 04763431 T PL04763431 T PL 04763431T PL 04763431 T PL04763431 T PL 04763431T PL 1660115 T3 PL1660115 T3 PL 1660115T3
Authority
PL
Poland
Prior art keywords
csf
useful
plgf
blood stem
stem cell
Prior art date
Application number
PL04763431T
Other languages
English (en)
Inventor
Alessandro Massimo Gianni
Carmelo Carlo-Stella
Francesco Colotta
Original Assignee
Dompe Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Spa filed Critical Dompe Spa
Publication of PL1660115T3 publication Critical patent/PL1660115T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL04763431T 2003-07-29 2004-07-23 Farmaceutyczna kombinacja G-CSF i PLGF użyteczna wobec komórek macierzystych krwi PL1660115T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03017174 2003-07-29
PCT/EP2004/008245 WO2005014023A1 (en) 2003-07-29 2004-07-23 Pharmaceutical combination of g-csf and plgf useful for blood stem cell
EP04763431A EP1660115B1 (en) 2003-07-29 2004-07-23 Pharmaceutical combination of g-csf and plgf useful for blood stem cell

Publications (1)

Publication Number Publication Date
PL1660115T3 true PL1660115T3 (pl) 2011-11-30

Family

ID=34130041

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04763431T PL1660115T3 (pl) 2003-07-29 2004-07-23 Farmaceutyczna kombinacja G-CSF i PLGF użyteczna wobec komórek macierzystych krwi

Country Status (21)

Country Link
US (1) US20070036747A1 (pl)
EP (1) EP1660115B1 (pl)
JP (1) JP4855253B2 (pl)
KR (1) KR101192136B1 (pl)
CN (1) CN100534528C (pl)
AT (1) ATE513555T1 (pl)
AU (1) AU2004262909B2 (pl)
BR (1) BRPI0412989A (pl)
CA (1) CA2526244C (pl)
DK (1) DK1660115T3 (pl)
ES (1) ES2369487T3 (pl)
IL (1) IL173369A (pl)
MX (1) MXPA06000017A (pl)
NO (1) NO20060955L (pl)
NZ (1) NZ543612A (pl)
PL (1) PL1660115T3 (pl)
PT (1) PT1660115E (pl)
RU (1) RU2351357C2 (pl)
SI (1) SI1660115T1 (pl)
WO (1) WO2005014023A1 (pl)
ZA (1) ZA200509361B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006218711B2 (en) 2005-03-02 2010-11-11 University Of Maryland, Baltimore Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
US20100048913A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US20110118219A1 (en) 2008-03-25 2011-05-19 University Of Maryland, Baltimore Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
US8785423B2 (en) 2008-04-14 2014-07-22 University Of Maryland, Baltimore Compositions and methods of inducing endoplasmic reticulum stress response for the treatment of cell proliferative diseases
CN102686600A (zh) 2009-02-05 2012-09-19 托凯药业股份有限公司 甾体cyp17抑制剂/抗雄激素物质的新型药物前体
GB2479693B (en) 2009-02-05 2014-04-09 Tokai Pharmaceuticals Inc Steroidal CYP17 inhibitors and their use in the treatment of cancer and prostate hyperplasia
CA2770092A1 (en) 2009-08-07 2011-02-10 Tokai Pharmaceuticals, Inc. Treatment of prostate cancer
KR102503695B1 (ko) 2013-02-28 2023-02-23 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 줄기세포를 동원하기 위한 방법 및 조성물
RU2015137617A (ru) 2013-03-14 2017-04-18 Юниверсити Оф Мэриленд, Балтимор Офис Оф Текнолоджи Трансфер Агенты, подавляющие андрогенные рецепторы, и их применение
CN105636594A (zh) 2013-08-12 2016-06-01 托凯药业股份有限公司 使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物
LT6161B (lt) 2013-09-27 2015-06-25 Uab Profarma Granuliocitų kolonijas stimuliuojančio faktoriaus sulieti baltymai su kitais augimo faktoriais, optimaliai su kamieninių ląstelių faktoriumi, ir jų gavimo būdas
CN114891746A (zh) * 2021-12-21 2022-08-12 青岛今墨堂生物技术有限公司 一种犬全血造血干细胞的制备方法
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
EP4716750A1 (en) 2023-05-23 2026-04-01 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5199942A (en) * 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
US5773252A (en) * 1995-06-05 1998-06-30 Human Genome Sciences, Inc. Fibroblast growth factor 15
DE19549232C2 (de) * 1995-12-20 1998-05-20 Boehringer Mannheim Gmbh Verwendung von G-CSF in Kombination mit einem Chemotherapeutikum bei der Behandlung von Erkrankungen, die eine periphere Stammzelltransplantation erfordern
US7105168B1 (en) * 2002-06-04 2006-09-12 D. Collen Research Foundation Vzw Method of improving ischemic muscle function by administering placental growth factor
EP1147777A1 (en) * 2000-04-18 2001-10-24 Crinos Industria Farmacobiologica S.p.A. Combination of defibrotide and G-CSF and its use to activate haematopoietic progenitors
WO2002022163A1 (en) * 2000-09-13 2002-03-21 Chugai Seiyaku Kabushiki Kaisha Remedies for ischemic diseases
DE10234192B4 (de) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
US20040248796A1 (en) * 2003-02-04 2004-12-09 Kari Alitalo VEGF-B and PDGF modulation of stem cells

Also Published As

Publication number Publication date
CN100534528C (zh) 2009-09-02
NZ543612A (en) 2008-03-28
EP1660115A1 (en) 2006-05-31
RU2006106228A (ru) 2007-09-10
ZA200509361B (en) 2007-03-28
US20070036747A1 (en) 2007-02-15
RU2351357C2 (ru) 2009-04-10
AU2004262909A1 (en) 2005-02-17
IL173369A0 (en) 2006-06-11
NO20060955L (no) 2006-02-27
ATE513555T1 (de) 2011-07-15
CA2526244A1 (en) 2005-02-17
BRPI0412989A (pt) 2006-10-03
IL173369A (en) 2010-12-30
MXPA06000017A (es) 2006-03-21
JP2007500157A (ja) 2007-01-11
KR101192136B1 (ko) 2012-10-16
PT1660115E (pt) 2011-08-24
JP4855253B2 (ja) 2012-01-18
KR20060079753A (ko) 2006-07-06
CA2526244C (en) 2012-03-20
CN1826134A (zh) 2006-08-30
WO2005014023A1 (en) 2005-02-17
EP1660115B1 (en) 2011-06-22
AU2004262909B2 (en) 2010-07-01
ES2369487T3 (es) 2011-12-01
SI1660115T1 (sl) 2011-10-28
DK1660115T3 (da) 2011-10-10

Similar Documents

Publication Publication Date Title
IL173369A0 (en) Pharmaceutical combination of g-csf and plgf useful for blood stem cell
WO2005021706A3 (en) Delivery of compounds with rehydrated blood cells
IL171683A (en) Immunosuppressive Compounds, Medicinal Products Containing Them and Their Use in the Preparation of Medication for Treatment
AU2002359340A1 (en) Methods and device compositions for the recruitment of cells to blood contacting surfaces in vivo
NO332893B1 (no) Anvendelse av antistoff for fremstilling av medikament til anvendelse ved CVP-kjemoterapi
WO2005025615A3 (en) FACTOR IXa SPECIFIC ANTIBODIES DISPLAYING FACTOR VIIIa LIKE ACTIVITY
PL1654253T3 (pl) Podstawione pochodne 3-pirolidynoindolu
MY143795A (en) Tetrahydropyridoindole derivatives
ZA200608029B (en) Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
WO2006125198A3 (en) Hemodialysis methods and apparatus
WO2006078782A3 (en) Compositions containing agm cells and methods of use thereof
EP2177531A3 (en) Cell permeable peptide
WO2005094554A3 (en) Therapeutic agents, methods, and treatments
EP1663201A4 (en) USE OF NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
WO2003079967A3 (en) Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue
WO2007008232A3 (en) Locoregional internal radionuclide ablation of abnormal tissues.
MXPA05011788A (es) Compuestos quimicos.
FR2883184B1 (fr) Composition de spirulines riche en principes actifs, procede d'obtention et utilisation
WO2004087876A3 (en) Use of red blood cells to facilitate cell activation
PL1663101T3 (pl) Postać stosowana do doustnego podawania substancji czynnych, witamin i/lub substancji odżywczych, zestaw i zastosowanie
WO2004087117A3 (de) Verwendung von cyclischen aketalen/ketalen zur verbesserten penetration von wirkstoffen in zellen und organen
PL1668021T3 (pl) Nowe związki tioksylozy, sposób ich przygotowania, zawierające je kompozycje farmaceutyczne i ich zastosowanie w lecznictwie
WO2008107785A3 (en) Composition containing autologous mononuclear cells and scaffold and its use in the preparation of a surgical medicament
HUP0203277A2 (en) Use of treosulfan for patient conditioning before bone marrow or blood stem cell transplantation
NO20071096L (no) Diarylmetylpiperazinderivater, fremstillinger derav og anvendelser derav